<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116164</url>
  </required_header>
  <id_info>
    <org_study_id>GID5490</org_study_id>
    <nct_id>NCT04116164</nct_id>
  </id_info>
  <brief_title>Safety and Targeting of Anti-hk2 Antibody in mCRPC</brief_title>
  <official_title>A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomopath Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Invicro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tomopath Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with
      mCRPC.

      This imaging study will be conducted to confirm the safety and estimate the mass amount of
      antibody h11B6, and confirm in vivo tumor targeting of the antibody, using Indium-111 (111In)
      radiolabeled h11B6 in subjects with advanced prostate cancer. This study will also provide
      the dosimetric information crucial for Phase 1 therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is the intent to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC.
      This Phase 0 study will be conducted to confirm the safety, estimate the mass amount, and
      confirm in vivo tumor targeting of the antibody. This study will use Indium-111 (111In)
      radiolabeled h11B6 in subjects with mCRPC to image known sites of disease and identify a
      favorable mass amount of antibody for satisfactory tumor targeting with minimal/no
      accumulation off-target. In cohort 1, In-111 labeled h11B6 will remain fixed at 2 mg, and
      additional h11B6 will be added in 2 sub-cohorts (8 mg and 18 mg respectively); up to 6
      patients may be entered into a sub-cohort. Additional patients (up to 6) will be studied once
      the most favorable mass and imaging time point have been established, to establish targeting
      of antibody to known disease.

      This study will provide the dosimetric information crucial for Phase 1 therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3-6 patients will be studied in each of 3 sub-cohorts to determine the most favorable mass amount of h11B6 (2 mg, 10 mg, 20 mg). An additional 6 patients will be imaged at the most favorable mass amount to assess tumor targeting.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum pharmacokinetics</measure>
    <time_frame>6 months</time_frame>
    <description>Serum clearance kinetics of 111In-DOTA-h11B6, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity Biodistribution</measure>
    <time_frame>6 months</time_frame>
    <description>Radioactivity residence times in liver, kidneys and tumor, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactivity accumulation in known tumor sites</measure>
    <time_frame>9 months</time_frame>
    <description>Number of known metastatic lesions in which there is increased uptake of 111In, in both cohorts 1 and 2.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Castration-Resistant Prostatic Cancer</condition>
  <condition>Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>Dosimetry and targeting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively.
In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111In-DOTA-h11B6</intervention_name>
    <description>4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.</description>
    <arm_group_label>Dosimetry and targeting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with mCRPC will be eligible if they meet the following criteria:

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 1

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Castrate levels of testosterone (&lt;50 ng/dL [1.74 nmol/L])

          -  Metastatic disease documented by imaging

          -  Documented progressive mCRPC with androgen involvement as defined by - Prostate Cancer
             Working Group 3

          -  Acceptable laboratory parameters

          -  At least 28 days since administration of any therapeutic radioactive isotope

          -  Able to tolerate the conditions required to perform imaging studies (e.g., lying flat
             for at least 1 hour).

        Exclusion Criteria:

          -  Known hypersensitivity to proteins, or other allergic diathesis that, in the opinion
             of the investigator, makes an immune response to humanized antibody likely

          -  Radiotherapy or immunotherapy within 30 days, or single fraction of palliative
             radiotherapy within 14 days of administration of study agent

          -  Any condition that, in the opinion of the Investigator, would impair the subject's
             ability to comply with study procedures and required study visits

          -  Active, symptomatic, or untreated brain metastases.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The study is being carried out in prostate cancer which afflicts only men.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Hospital for Cancer and Allied Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Morris, MD</last_name>
    <phone>646-497-9068</phone>
    <email>morrism@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neeta Pandit-Taskar, MD</last_name>
    <phone>212-639-3046</phone>
    <email>pandit-n@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Morris, MD</last_name>
      <phone>646-497-9068</phone>
      <email>morrism@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Neeta Pandit-Taskar, MD</last_name>
      <phone>212-639-3049</phone>
      <email>pandit-n@mskcc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology. 1997 Jun;49(6):857-62.</citation>
    <PMID>9187691</PMID>
  </reference>
  <reference>
    <citation>Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Sci Transl Med. 2016 Nov 30;8(367):367ra167.</citation>
    <PMID>27903863</PMID>
  </reference>
  <reference>
    <citation>Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost. 2013 Sep;110(3):484-92. doi: 10.1160/TH13-04-0275. Epub 2013 Aug 1. Review.</citation>
    <PMID>23903407</PMID>
  </reference>
  <reference>
    <citation>Vilhelmsson Timmermand O, Larsson E, Ulmert D, Tran TA, Strand S. Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2. EJNMMI Res. 2016 Dec;6(1):27. doi: 10.1186/s13550-016-0181-z. Epub 2016 Mar 17.</citation>
    <PMID>26983637</PMID>
  </reference>
  <reference>
    <citation>McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, Larson SM, Ulmert D. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w.</citation>
    <PMID>29691406</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiolabeled antibody</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

